Skip to main content

Table 4 Number of findings of bursitis and effusion/synovitis, defined as a scorea ≥ 2, at baseline and at week 12, and percentages of abnormalities whose scores fell below 2 between baseline and week 12

From: Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab

  

Baseline

Week 12

Grade < 2

MRI

Four joints

82/116

45/82

45% (37/82)

Bursitisb

42/58

17/42

60% (25/42)

Effusion/synovitisc

40/58

28/40

30% (12/40)

US

Four joints

24/116

5/24

71% (17/24)

Bursitisb

9/58

0/9

100% (9/9)

Effusion/synovitisc

15/58

5/15

67% (10/15)

  1. MRI magnetic resonance imaging US ultrasonography
  2. aOMERACT Outcome Measures in Rheumatology score on a 0–3 scale, where 0 is normal
  3. bBursitis: subacromial bursitis at the shoulders and trochanteric and iliopsoas bursitis at the hips
  4. cShoulders: glenohumeral joint and long head of biceps; hips: coxofemoral joints